Key Points {#d30e195}
==========

Our modelling suggests that the use of measles, mumps, rubella, and varicella combination vaccines (MMRV) instead of measles, mumps, and rubella vaccine with varicella vaccine (MMR + V) can substantially reduce the number of hospitalisation days via higher vaccination coverage against varicella, despite the observed increased risk of febrile convulsions when MMRV is used as a first dose of measles-containing vaccine.The net result of these two opposing effects is one of the trade-offs between the two vaccination schemes that needs to be considered when making decisions on their use in immunisation programmes.This proof-of-concept analysis has demonstrated the feasibility and usefulness of quantitative modelling approaches, based on the combination of heterogeneous data sources, to provide objective, rational, and transparent information.

Introduction {#Sec1}
============

Combination vaccines are used to simplify the recommended immunisation schedules, decrease the number of healthcare visits and injections in children, and improve vaccination coverage and compliance \[[@CR1], [@CR2]\]. Therefore, measles, mumps, rubella, and varicella combination vaccines (MMRV) have been developed to replace the separate administration of the trivalent measles, mumps, and rubella vaccine (MMR) with the monovalent varicella vaccine (V). As seen with other combination vaccines, MMRV has been a key driver in improving the vaccination coverage against varicella in various countries, such as Germany and the USA \[[@CR3]--[@CR8]\].

German data suggest that V uptake was suboptimal when separate administration of MMR + V was recommended. Indeed, some parents are willing to vaccinate their child against MMR, but do not accept separate V and MMR vaccination. The main factors associated with the low acceptance rate of V vaccination by parents are the recommendations of paediatricians, who often have doubts about the benefits of varicella vaccination as they rarely observe severe complications in their practices; a negative attitude towards vaccination in general; parents doubts about vaccine safety and effectiveness; and the perception that varicella is a mild disease \[[@CR5], [@CR7], [@CR8]\]. Data from Germany, where MMRV was introduced in 2006, also showed that, even when MMRV was widely used, varicella vaccination coverage and timeliness of vaccination could still be improved \[[@CR9]\]. Data from a national sentinel network led by the Robert Koch Institute suggested that varicella vaccination coverage in Germany was 78 % in 2008 \[[@CR10]\]; however, this could be an overestimation of the real coverage since the network may not be representative of the entire country \[[@CR6]\].

In children, the risk of febrile convulsions (FC) is increased during the first 2 weeks following MMR vaccination \[[@CR11], [@CR12]\]. In addition, more recent studies have shown that this risk was about two times higher in children vaccinated with the first MMRV vaccine licensed worldwide (ProQuad^®^, Merck & Co., Inc., Whitehouse Station, New Jersey, USA) compared with the separate administration of MMR + V \[[@CR13], [@CR14]\]. Later, a study conducted by the Bremen Institute for Epidemiology and Prevention Research showed that the risk of developing FC within 5--12 days post-vaccination was also higher in children younger than 5 years who received the other licensed MMRV vaccine (Priorix-Tetra™, GSK, Belgium) compared with separate injections of MMR + V or MMR alone \[[@CR15]\]. A further study provided similar risk estimates from Canada \[[@CR16]\]. These observations suggest that both MMRV vaccines, when used as a first dose of measles-containing vaccine, are associated with an increased risk of FC \[[@CR17]\].

While combined MMRV vaccines can potentially increase the number of FC cases, they can decrease the number of varicella cases through increased coverage for the V component. Here, we present an attempt to assess the net result of these two opposing effects (Fig. [1](#Fig1){ref-type="fig"}). This comparison would ideally be made by counting the hospitalisations for FC and varicella, and their duration, in a number of large populations randomly allocated to MMRV and MMR + V schemes, over several years, and with everything else being equal. As this is hardly feasible, we selected a modelling approach and the recent experience in Germany as a starting point. In Germany, a general varicella immunisation for infants from the age of 11 months was introduced in 2004, followed by the subsequent recommendation of a second vaccine dose at 15--23 months of age in 2009. Priorix-Tetra™ was licensed in July 2006, and both vaccination schemes (MMR + V and MMRV) have been widely used; this has favoured comparison between the two vaccination regimens in a previous study conducted by the Bremen Institute for Epidemiology and Prevention Research \[[@CR15]\]. In our analysis, we first used German data to put the increased risk of FC associated with MMRV (Priorix-Tetra™) into perspective by comparing it with the higher risk of varicella infection associated with the MMR + V regimen. Then, we expanded this analysis to other scenarios beyond the German experience.Fig. 1Schematic representation of the two competing vaccination schemes and their associated risks and benefits as selected for the current analysis. \*The (small) fraction of the total population who is not properly vaccinated against MMR. *FC* febrile convulsions, *MMR* measles, mumps, and rubella vaccine, *MMRV* measles, mumps, rubella, and varicella vaccine, *V* varicella vaccine

Methods {#Sec2}
=======

In this quantitative analysis, the increased risk of FC associated with MMRV (Priorix-Tetra™) was contrasted with the higher risk of varicella infections associated with the separate MMR + V vaccination approach (Fig. [1](#Fig1){ref-type="fig"}). We used a model based on several assumptions to integrate parameters from heterogeneous sources of data from Germany (in the period 2006--2008). Statistical uncertainty was evaluated through a probabilistic uncertainty analysis by Monte Carlo simulations. In addition, to address the potential variability between countries or over time, structural uncertainty was assessed through a sensitivity analysis.

The assumptions, as well as the point estimates for the input parameters, are described in Table [1](#Tab1){ref-type="table"}, and were selected to mimic the situation in Germany in the period 2006--2008. The risk estimates were derived from the post-marketing study conducted by the Bremen Institute for Epidemiology and Prevention Research among children who received a first vaccination with MMRV (Priorix-Tetra™), MMR, or MMR + V between January 2006 and December 2008 \[[@CR15]\]. Whereas the German vaccination programme changed to a two-dose schedule for MMRV or MMR + V in 2009, only the first doses were taken into account in this population-based analysis.Table 1Definitions and point estimates of the input parameters, and uncertainty of these parameters observed in the Monte Carlo simulationsParameterPoint estimateSourcesDistributionSimulation, median (95 % CI)P1Incidence of FC in days 5--12 after MMRV (number of FC per child)51/82,436\[[@CR15]\]Poisson61.9 (46.1--78.9)^a^P2Incidence of FC in days 5--12 after MMR (number of FC per child)21/82,469\[[@CR15]\]Poisson25.5 (15.8--36.4)^a^P3Relative probability of hospitalisation for FC as compared with the German data from 2006--20081.0\[[@CR15]\]Constant1 (--)P4Number of hospitalisations for varicella per year (before the introduction of routine vaccination against varicella, across all age groups)1996\[[@CR24]\]Normal1998 (1365--2633)P5Median LOS for FC (number of days)1\[[@CR26]\]Constant1 (--)P6Median LOS for varicella (number of days)5\[[@CR24]\]Poisson5 (1--10)P7MMR coverage for the first dose0.9\[[@CR8]\]Constant0.9 (--)P8Probability of V vaccination along with MMR vaccination0.78\[[@CR10]\]Constant0.78 (--)P9German birth cohort size (year 2005)685,795National statisticsConstant685,795 (--)*CI* confidence interval, *FC* febrile convulsions, *LOS* length of stay in hospital, *MMR* measles, mumps, and rubella vaccine, *MMRV* measles, mumps, rubella, and varicella vaccine, *P* parameter, *V* varicella vaccine^a^Cumulative incidence per 100,000 children

The primary health outcome in this analysis was the duration of hospitalisation (median length of stay), which was chosen as a measure of the burden of both FC and varicella infection. Yearly attributable numbers of hospitalisation days were estimated for each vaccination regimen. The secondary health outcome in this analysis was the number of hospitalisations.

Modelling Assumptions {#Sec3}
---------------------

The model was based on the following assumptions:Vaccination with V occurred only in co-administration with MMR.MMR vaccination coverage and effectiveness were considered as identical between the MMR + V and the MMRV regimens.Vaccination coverage of V varied between the two vaccination regimens.Vaccine effectiveness of V was considered identical under both vaccination regimens \[[@CR18]--[@CR20]\].One dose of V conferred identical and total protection against varicella-related hospitalisation under both vaccination regimens \[[@CR21]\].The two vaccination regimens were compared as if they had been implemented for a sufficient amount of time as to reach a steady state in the dynamics of the disease, and all effects were assumed to be linear \[[@CR22]\].The incidence of adverse events leading to hospitalisation, other than FC in the period of 5--12 days after the first dose, were considered identical under both vaccination regimens \[[@CR18], [@CR23]\].There were no health consequences later in life from hospitalisation for FC or varicella \[[@CR24], [@CR25]\].The number of hospitalisations for varicella after introduction of routine varicella vaccination was linearly proportional to the proportion of unvaccinated children.

Calculation of the Hospitalisation Ratio {#Sec4}
----------------------------------------

To quantify the benefit, we calculated the number of hospitalisation days and the number of hospitalisations for varicella that could be averted when using MMRV instead of MMR + V. The hospitalisation rate for varicella in unvaccinated children was based on the yearly number of varicella-related hospitalisations observed in Germany before the introduction of routine varicella vaccination. The yearly number of varicella-related hospitalisation days and hospitalisations attributable to MMR + V compared with MMRV were estimated as follows (Table [1](#Tab1){ref-type="table"}): (P6) × (P4) × (P7) × \[1 − (P8)\] and (P4) × (P7) × \[1 − (P8)\], respectively.

To quantify the risk, we calculated the yearly number of hospitalisation days and the number of hospitalisations for FC that were attributable to MMRV compared with MMR or MMR + V. The yearly population at risk was the fraction of the birth cohort vaccinated with MMRV. The yearly number of hospitalisation days and hospitalisations for FC attributable to MMRV compared with MMR + V were estimated from the differences between the incidence of FC under both vaccination regimens as follows (Table [1](#Tab1){ref-type="table"}): (P5) × (P9) × (P7) × \[(P1) − (P2)\] × (P3) and (P9) × (P7) × \[(P1) − (P2)\] × (P3), respectively.

The hospitalisation ratio (HR) was the ratio between the excess number of hospitalisation days (primary outcome) or hospitalisations (secondary outcome) attributable to varicella when vaccinating with MMR + V compared with MMRV, and the excess number of hospitalisation days (primary outcome) or hospitalisations (secondary outcome) attributable to vaccine-related FC when vaccinating with MMRV compared with MMR + V.

Probabilistic Uncertainty Analysis {#Sec5}
----------------------------------

The statistical variability of each non-constant input parameter of the model was used to evaluate the statistical uncertainty of the HR through a probabilistic analysis based on Monte Carlo simulations. The most relevant statistical distribution was selected for each input parameter, and 100,000 sets with randomly generated values for all input parameters were produced. The point estimate from the Monte Carlo simulation was defined as the median of the 100,000 values, and the 95 % confidence interval (CI) was derived from the observed percentiles.

Rather surprisingly, data from the Bremen Institute for Epidemiology and Prevention Research indicated a median duration of hospitalisation for FC of 2--3 days during the first month following MMR or MMRV vaccination in 2006--2008, with several cases having a relatively long duration of up to 17 days. However, since the most recent German guidelines include no indication on whether children with FC should be hospitalised or not, the duration of hospitalisation for FC was based on the most recent international recommendations \[[@CR26]\] and set to a value of 1 day in this analysis (Table [1](#Tab1){ref-type="table"}). A study conducted in 1985 in the UK already suggested that children who had been observed for 24 h after FC could be discharged from hospital if the diagnosis of the cause of fever had been established and the children were medically fit, even if they were still febrile \[[@CR27]\]. With current vaccination schedules, the risk of meningitis has become extremely low, and it is not recommended anymore to carry out unnecessary investigations in most children presenting with FC \[[@CR26]\].

Current international recommendations for the management of FC advocate minimal intervention \[[@CR26]--[@CR29]\]. In Germany, the Bremen Institute for Epidemiology and Prevention Research reported that hospitalisation rates for FC in 2006--2008 were around 60 % in 9- to 17-month-old children; this estimation was based on different case definitions for hospitalised and non-hospitalised children, and did not take into account the timing of MMR or MMRV vaccination. In a study conducted in the USA, hospitalisation rates for FC were 6 and 17 % during 7--10 days following MMRV and MMR + V vaccination, respectively \[[@CR14]\]. In another study, hospitalisation rates dropped significantly after implementation of updated guidelines for the management of children with FC (from 57.3 to 20.5 % and from 16.9 to 3.2 % in two large hospitals in France and Italy, respectively) \[[@CR28]\].

Sensitivity Analysis {#Sec6}
--------------------

We identified the two parameters that are most likely to vary largely between countries or over time and have a large effect on the HR: rates of hospitalisation for FC and vaccination coverage for V under MMR + V. A sensitivity analysis was conducted to explore the structural uncertainty of HR in situations where the values of these two parameters were changed over their potential range. Monte Carlo simulations were used to derive the different values of both the relative probability of hospitalisation for FC as compared with the German data from 2006--2008 (parameter P3) and the vaccination coverage for V under MMR + V (parameter P8), for which the point estimates for the HR were 1. Statistical uncertainty was estimated as explained above.

In the study of the Bremen Institute for Epidemiology and Prevention Research, the probability of hospitalisation for FC was 100 % by definition since only hospitalised cases were included in the analysis \[[@CR15]\]. However, in the German national context, the probability of hospitalisation for FC is not 100 % and is considered to be close to 80 %. To allow for generalisation, the model was slightly modified in order to use the national probability of hospitalisation for FC instead of the one related to the specific study of the Bremen Institute for Epidemiology and Prevention Research.

In order to differentiate the parameter space where the HR could be considered to be significantly higher than 1, we also derived the parameter values for which the lower limit of the 95 % CI around the HR was 1.

Results {#Sec7}
=======

Modelling Based on the German Experience {#Sec8}
----------------------------------------

The estimates for the different input parameters used in the model were selected from heterogeneous sources of data as described in Table [1](#Tab1){ref-type="table"} \[[@CR8], [@CR10], [@CR15], [@CR24]\]. When using these point estimates for all parameters, the model predicted 1976 days of hospitalisation (395.4 hospitalisations) for varicella averted when the MMRV vaccination regimen was used, compared with 225 days of hospitalisation (225.0 hospitalisations) for FC attributable to MMRV. The point estimate of the HR was close to 11 in the primary analysis, which was based on the number of hospitalisation days.

When the random variability of each non-constant input parameter of the model was estimated by a Monte Carlo probabilistic uncertainty analysis, the median HR was 8.48 (95 % CI: 1.99--25.22) in terms of hospitalisation days and 1.76 (0.98--4.02) in terms of number of hospitalisations (Table [2](#Tab2){ref-type="table"}). The difference with the point estimate presented above may be explained by the non-symmetrical distribution of the HR. In the primary analysis, the lower limit of the 95 % CI around the HR was above 1, indicating that the number of hospitalisation days attributable to non-prevented varicella when using MMR + V as compared with MMRV was significantly higher than the number of hospitalisation days attributable to FC after MMRV as compared with MMR + V at a 95 % CI (Table [2](#Tab2){ref-type="table"}).Table 2Benefit and risk estimates in terms of number of hospitalisation days in GermanyNameMeanMedian95 % CIYearly number of hospitalisation days for FC attributable to MMRV (risk)225.0224.7104.9--351.9Yearly number of hospitalisation days for varicella prevented under MMRV (benefit)19891879433.4--4125Hospitalisation ratio8.51.995--25.22*CI* confidence interval, *FC* febrile convulsions, *MMRV* measles, mumps, rubella, and varicella vaccine

Sensitivity Analysis {#Sec9}
--------------------

Expected outcomes in other countries or under different scenarios were derived from a sensitivity analysis, which was based on two key parameters: the vaccination coverage of V when co-administered with MMR and the probability of being hospitalised for FC. The point estimate of the HR in terms of hospitalisation days was higher than 1 for scenarios where the probability of being hospitalised for FC was less than 40 times the probability of not receiving V along with MMR (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Estimates of the HR in terms of number of hospitalisation days under different scenarios. *CI* confidence interval, *FC* febrile convulsions, *HR* hospitalisation ratio, *MMR* measles, mumps, and rubella vaccine, *V* varicella vaccine

In countries where the mean duration of hospitalisation for varicella was different than in Germany (e.g. 3 days instead of 5 days), the slope of the discriminating line, which is shown in Fig. [2](#Fig2){ref-type="fig"}, would be corrected by the same ratio (e.g. 40 × 3/5 = 24). When considering the line for the 95 % CI limit in Fig. [2](#Fig2){ref-type="fig"}, the main driver was the probability of not receiving V along with MMR.

Discussion {#Sec10}
==========

The results of our analysis using German data suggested that the predicted number of hospitalisation days induced by the increase risk of FC associated with MMRV is lower than that induced by higher risk of varicella infection associated with the MMR + V regimen. The expansion of this analysis to other scenarios beyond the German experience suggested that transitioning from MMR + V to MMRV would be favourable in situations where MMRV use would significantly impact varicella vaccination uptake.

For parameter values compatible with the recent experience in Germany, the model suggested that transitioning from MMR + V to MMRV would reduce the yearly number of hospitalisation days; although there may be 225 hospitalisation days attributable to vaccine-related FC, at the same time, 1976 hospitalisation days due to severe varicella could be averted by using MMRV instead of MMR + V. When Monte Carlo simulations were used to evaluate the statistical uncertainty, the median HR was estimated to be 8.5 (95 % CI 1.99--25.22). Since these estimations were derived from a model based on several assumptions and using heterogeneous sources of data, this quantitative analysis should be used along with other relevant considerations for any overall benefit/risk assessment of MMRV compared with MMR + V.

A sensitivity analysis was performed to estimate HR under different scenarios, which were based on existing or hypothetical situations, and could represent other countries or other times when vaccine recommendations or use were different. This modelling approach, with all its limitations, suggested that, in situations where MMRV use would significantly impact varicella vaccination uptake, the use of MMRV instead of MMR + V would be favourable. For any further use of these results, it is critical to consider the model assumptions and assess their relevance before making any decision on the use of MMRV in immunisation programmes.

The results are based on a modelling approach with several limitations, including:The model did not consider situations where V was co-administered with the second MMR dose (either as MMR + V or MMRV) if it was not co-administered with the first MMR dose.The assumption of total protection against hospitalisation could have overestimated the benefit measure of the MMRV compared with the MMR + V vaccination regimen.The measures of the burden of both FC and varicella infection that were selected in this analysis (days of hospitalisation and number of hospitalisations) may not have completely captured the severity of the two medical conditions; hospitalisation for FC is generally more a measure of precaution, while hospitalisation related to varicella infection generally indicates a serious medical concern.The model did not take into account the potential impact of the recommendation to administer the first doses of MMR and V separately in Germany since 2011 \[[@CR3]\].The model did not take into account the effect of herd immunity, which is relevant in the context of protection against varicella. This is a conservative approach since such an effect would increase the benefit of MMRV compared with MMR + V.

Conclusion {#Sec11}
==========

A modelling approach can be used to estimate the overall impact of different vaccine regimens on some specific outcomes. The model used in this analysis suggested that transitioning from MMR + V to MMRV may substantially reduce the number of hospitalisation days, despite the observed increased risk of FC when MMRV was used as a first dose of measles-containing vaccine. This proof-of-concept analysis has demonstrated the feasibility and usefulness of quantitative modelling approaches, based on the combination of heterogeneous data sources, to provide objective, rational, and transparent information. However, all assumptions and limitations should be kept in mind. In addition, our model only assessed one of the multiple trade-offs between the two vaccination regimens that need to be considered when making decisions on their use in immunisation programmes. In the future, more extensive research could be performed to address unanswered questions, such as analyses using quality-adjusted life-years as an outcome instead of the length and number of hospitalisations, and analyses taking into account indirect effects, such as herd immunity or increased hesitancy to accept MMRV due to knowledge of the increased risk of FC.
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